

Published in final edited form as:

Org Lett. 2006 December 21; 8(26): 6047–6049. doi:10.1021/ol0624676.

Synthesis of an Advanced Intermediate En Route to the Mitomycin Natural Products


 Amie L. Williams[§], Jayasree M. Srinivasan[§], and Jeffrey N. Johnston*

Department of Chemistry, Vanderbilt University, Nashville, TN 37235-1822

Abstract

An advanced intermediate in our planned synthesis of mitomycin C has been acquired in nine steps from *tert*-butyl glyoxylate. The aziridinyl pyrrolidine and quinone subunits are coupled regioselectively to arrive at an enamine that is prepared for C10 homologation.

The mitomycin natural products have attracted the attention of medicinal and synthetic chemists for nearly a half century.^{1,2} This interest results from several factors, including the continued clinical use of mitomycin C (**1**) for treatment of various forms of cancer. The unique pyroloquinone backbone presents a high degree and density of oxidation, and this functional group array is the source of mitomycin C's unique ability to crosslink DNA.³ Consequently, a substantial challenge for chemical synthesis is presented. Indeed, there have been many reports detailing synthetic efforts toward this class of natural products, and although interest has not waned with the passing of time, only two total syntheses of the title compound⁴ and two syntheses of another member of the class, mitomycin K (**3**)⁵, have been logged.



A successful synthesis, particularly one amenable to derivative formation, might further improve the therapeutic profile for this natural product class,⁶ and rejuvenate efforts to use contemporary biochemical techniques to similarly improve efficacy.

To achieve a high degree of convergency, our retrosynthesis disconnects the aziridinopyrrolidine and quinone across the central dihydropyrrole ring. On the basis of our previous studies of regioselective enamine additions to methoxy quinones,⁷ we expected the coupling of enamine **6** to quinone **7** to be regioselective for methoxy substitution at the bromomethoxy olefin.⁸ Construction of enamine **6** could arise from a cyclization of an amino alkyne via formal alkyne hydroamination. Convergency could again be served if an aziridine ring-forming reaction could be used that would also form the aziridine carbon-carbon bond. Hence, we began our studies by investigating the traditional methods for aziridine construction by carbon-carbon bond formation.⁹

jeffrey.n.johnston@vanderbilt.edu.

[§]Indiana University, Bloomington, IN 47405.

Scheme 1 lists several general lines of investigation toward this end. Based on the work of O'Donnell¹⁰ and Miller,¹¹ we anticipated that glycinyl Schiff base **8** might engage propargyl aldehyde **7** in an aldol reaction. The resulting β -hydroxy ester could be converted to the corresponding mesylate. In order to avoid competitive cyclization to the corresponding oxazoline,¹² *in situ* trapping with mesyl chloride was necessary. Reductive amination then provided the desired aziridine in good overall yield. Unfortunately, the initial addition was minimally diastereoselective and favored the undesired *trans*-isomer.

The Darzens reaction¹³ using an azomethine electrophile provided a more direct route to the aziridine since it avoided the necessity to activate the hydroxy imine intermediate in eq 1 and reduce the imine functionality.¹⁴ The reaction of propargyl imine **10** under these conditions provided only trace amounts of aziridine, much less the desired *cis*-**9**. By activating the imine electrophile without resorting to a more robust protecting group at nitrogen, we examined the diphenylmethyl amine Schiff base of ethyl glyoxylate (**11**). Combination of the reactants at low temperature, followed by slow warming to room temperature, resulted in modest yields of the desired aziridine. Of greater significance is the high *cis*-diastereoselection observed in this transformation, a prerequisite for eventual formation of the aziridinopyrrolidine. Substitution of chloroacetonitrile for *tert*-butyl chloroacetate was also effective and *cis*-selective, but provided a greater amount of competing nitrile homocoupling.

Conversion of the *cis*-aziridiniosuccinate **12** to enamine precursor **16** (Scheme 2) began with selective saponification of the ethyl ester using aqueous sodium hydroxide in ethanol (97%). Straightforward coupling of the carboxylic acid with commercial (*S*)- α -methyl benzylamine (98% ee) was achieved in 74% yield using DCC/HOBT to furnish diastereomeric *cis*-aziridines **14a/b**. Selective reduction of *tert*-butyl ester **14** provided the corresponding aldehydes in good yield as judged by spectroscopic analysis of the crude reaction mixture. Careful chromatographic separation at this stage provided the diastereomeric *cis*-aziridines in pure form, however at the expense of chemical yield due to their instability. Subsequent alkynylation of the less polar aldehyde was effected using the Gilbert-Seyferth phosphonate reagent.¹⁵ In this manner, the terminal alkyne was produced in 85% yield from **14a**. Red-Al reduction of the amide was similarly effective, and alkynyl amine **16a** was obtained in 79% yield. Upon standing for one week, this amine crystallized and single crystals could be obtained by slow evaporation from dichloromethane. X-ray crystallographic analysis enabled assignment of the stereochemistry depicted in Scheme 2.

An aminomercuration/coupling sequence was next evaluated with quinone **5** (Scheme 3). Enamine **6b** was generated *in situ* by treatment of alkynylamine **16b**¹⁶ with Hg(II),¹⁷ and this solution was added to quinone **5**. The resulting deep blue solution was concentrated at 0 °C. Analysis of this crude reaction mixture by ¹H NMR suggested selective and efficient production of a coupled product (see SI for details). However, successful purification of the putative enamine required cold column chromatography (ice water cooling). Using the bright color of the conjugated system as an indicator during this process, a product was isolated and kept at low temperature during NMR analysis. Notwithstanding, the material decomposed slowly with an approximate half-life of 1.5 days at -15 °C. The reactivity of this intermediate, manifested as instability during purification, is a feature we anticipated and desired as part of our synthesis strategy; notwithstanding, we sought to fully characterize it by spectroscopic means.

Immediate recognition of several features suggested its identity to be **4b**. The aminobenzyl methine proton resonances are readily differentiated by chemical shift. The methine of the enamine is consistently deshielded to 4–5 ppm. The corresponding aziridine DPM-methine is further upfield at 3–4 ppm. HMBC, HMQC, and COSY experiments allowed assignment of all proton and carbon resonances. The coupling regiochemistry was identified by ³J_{CH} between

the enamine proton resonance (H9) and the quinone carbonyl carbon (C8) nearest the methoxy substituent. The latter was assigned indirectly by identification of the companion quinone carbonyl (C5) for which a $^3J_{CH}$ crosspeak could be observed from the quinone ring methyl substituent. Consistent with our earlier observation, the methoxy group is preferentially substituted despite the electronic counter-influence of the distal methoxy. This behavior is consistent with rate-limiting addition in this nucleophilic vinylogous acyl substitution. The geometry of the newly formed enamine olefin was assigned by analogy to similar reactions we have investigated, all of which provide the *E*-olefin stereoisomer.⁷

In summary, we have arrived at an advanced intermediate (**4**) in our approach to the synthesis of the antitumor agent mitomycin C. This is accomplished in only nine steps from ethyl glyoxylate. The next significant step is homologation to install the C10 hydroxymethyl; the enamine character of **4**, as well as the steric influence of the aziridine are perfectly suited to this task. Details on this front will be the subject of future reports.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We are grateful to the National Institutes of Health (GM-63577) for support of this work. A.L.W. (IU) is the recipient of a Procter & Gamble graduate fellowship. J.N.J. (VU) is grateful for young investigator awards from Eli Lilly, Amgen, Astellas, and Boehringer-Ingelheim. We acknowledge the assistance provided by Dr. Doug Brown for the low temperature NMR experiments, and by Maren Pink for the X-ray structural determination of **16a**.

References

1. Isolation and initial structure determination. (a) Webb JS, Cosulich DB, Mowat JH, Patrick JB, Broschard RW, Meyer WE, Williams RP, Wolf CF, Fulmor W, Pidacks C, Lancaster JE. *J. Am. Chem. Soc* 1962;84:3185. (b) Webb JS, Cosulich DB, Mowat JH, Patrick JB, Broschard RW, Meyer WE, Williams RP, Wolf CF, Fulmor W, Pidacks C, Lancaster JE. *J. Am. Chem. Soc* 1962;84:3187. (c) Tulinsky A. *J. Am. Chem. Soc* 1962;84:3188.
2. Selected recent leading references: (a) Coleman RS, Felpin F-X, Chen W. *J. Org. Chem* 2004;69:7309. [PubMed: 15471485] (b) Vedejs E, Little J. *J. Am. Chem. Soc* 2002;124:748. [PubMed: 11817939] (c) Papaioannou N, Evans CA, Blank JT, Miller SJ. *Org. Lett* 2001;3:2879. [PubMed: 11529780] (d) Ziegler FE, Berlin MY, Lee K, Looker AR. *Org. Lett* 2000;2:3619. [PubMed: 11073659] (e) Ban Y, Nakajima S, Yoshida K, Mori M, Shibasaki M. *Heterocycles* 1994;39:657. (f) Lee J, Ha JD, Cha JK. *J. Am. Chem. Soc* 1997;119:8127. (g) Luly JR, Rapoport H. *J. Org. Chem* 1984;49:1671.
3. (a) Tomasz M. *Chem. Biol* 1995;2:575. [PubMed: 9383461] Sheldon PJ, Johnson DA, August PR, Liu H-W, Sherman DH. *Dev. Ind. Microbiol* 1997;34:123. (b) Gargiulo D, Musser SS, Yang L, Fukuyama T, Tomasz M. *J. Am. Chem. Soc* 1995;117:9388. Verweij, J.; Sparreboom, A.; Nooter, K. Ch. 3. In: Pinedo, HM.; Longo, DL.; Chabner, BA., editors. *Cancer Chemotherapy and Biological Response Modifiers Annual*. New York: Elsevier; 1999. (d) Crown JP. *Anti-Cancer Drugs* 1999;10:S19. [PubMed: 10630364]
4. *rac-1,2*: (a) Kishi Y, Fukuyama T. *J. Nat. Prod* 1979;42:549. (b) Fukuyama T, Yang L. *J. Am. Chem. Soc* 1989;111:8303.
5. *rac-3*: (a) Benbow JW, Schulte GK, Danishefsky SJ. *Angew. Chem. Int. Ed. Engl* 1992;31:915. See also (b) Danishefsky SJ, Schkeryantz JM. *Synlett* 1995:475. (c) Wang Z, Jiminez LS. *Tetrahedron Lett* 1996;37:6049.
6. Kasai M, Kono M. *Synlett* 1992:778.
7. Cox AL, Johnston JN. *Org. Lett* 2001;3:3695. [PubMed: 11700115]
8. (a) Theodorakis EA, Ling T, Rueden EJ, Poupon E, Kim SH. *Strat. Tactics Org. Synth* 2004;5:111. (b) Ling T, Poupon E, Rueden RJ, Kim SH, Theodorakis EA. *J. Am. Chem. Soc* 2002;124:12261. [PubMed: 12371868] (c) Ling T, Poupon E, Rueden EJ, Theodorakis EA. *Org. Lett* 2002;4:819.

- [PubMed: 11869136] (d) Stagliano KW, Lu Z, Emadi A, Harwood JS, Harwood CA. *J. Org. Chem* 2004;69:5128. [PubMed: 15255750]
9. (a) Sweeney JB. *Chem. Soc. Rev* 2002;31:247. [PubMed: 12357722] (b) Graham MA, Thornton-Pett M, Rayner CM, Wadsworth AH. *Chem. Commun* 2001:966.
10. O'Donnell, MJ. Ch. 10. In: Ojima, I., editor. *Catalytic Asymmetric Synthesis*. 2nd ed. New York: Wiley-VCH; 2000.
11. Gasparski CM, Miller MJ. *Tetrahedron* 1991;47:5367.
12. (a) Van Ornum SG, Bruendl MM, Cao H, Reddy M, Grubisha DS, Bennett DW, Cook JM. *J. Org. Chem* 2000;65:1957. [PubMed: 10774014] (b) MacMillan JB, Molinski TF. *Org. Lett* 2002;4:1883. [PubMed: 12027638]
13. Darzens G. *Compt. Rend* 1904;139:1214.
14. (a) Wartski L. *J. Chem. Soc. Chem. Commun* 1977:602. (b) Cainelli G, Panunzio M. *Tetrahedron Lett* 1991;32:121. (c) Vedejs E, Piotrowski DW, Tucci FC. *J. Org. Chem* 2000;65:5498. [PubMed: 10970287]
15. (a) Seyferth D, Marmor RM, Hilbert PH. *J. Org. Chem* 1971;37:1379. (b) Gilbert JC, Weerasooriya U. *J. Org. Chem* 1979;44:4997. (c) Ohira S. *Synth. Commun* 1989;19:561. (d) Muller S, Liepold B, Roth GJ, Bestmann HJ. *Synlett* 1996:521.
16. The decision to use diastereomer *cis-16b* (as opposed to *cis-16a*) was rather arbitrary, determined by the available pure diastereomer at the time.
17. (a) Barluenga J, Aznar F, Liz R, Rodes R. *J. Chem. Soc. Perkin Trans 1* 1980:2732. (b) Barluenga J, Aznar F, Liz R. *Synthesis* 1984:304. (c) Barluenga J, Aznar F, Cabal MP. *Synthesis* 1986:960.







Figure 1.
Retrosynthesis of mitomycin C

glycine aldol, aziridine ring formation




- low overall yield
- low diastereoselection
- trans*-selective

base-promoted aza-Darzens




- moderate yield
- high diastereoselection
- cis*-selective




- low yield
- high diastereoselection
- cis*-selective

Scheme 1.

Approaches to the synthesis of *cis*-aziridine precursors to **6**



Scheme 2.
Synthesis of alkyne amine **16**
* then separate diastereomers



Scheme 3.
Formation of the key enamine intermediate and subsequent alkylation to the mitomycin backbone